Protecting Dynorphin from Breakdown Extends Its Pain-Relieving Effects

Peptidase inhibitors significantly prolonged dynorphin A and B's pain-relieving effects when injected into the spinal cord, confirming rapid enzymatic breakdown limits their natural analgesic duration.

Tan-No, K et al.·European journal of pharmacology·1996·Moderate EvidenceAnimal StudyAnimal Study
RPEP-00389Animal StudyModerate Evidence1996RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Peptidase inhibitors significantly prolonged the antinociceptive effect of intrathecally administered dynorphin A (0.5-2 nmol) and dynorphin B (2-8 nmol) in the formalin test.

Key Numbers

How They Did This

Mouse formalin test: dynorphin A or B was injected intrathecally 5 minutes before 0.5% formalin injection into a hindpaw. Pain response was measured with and without co-administered peptidase inhibitors.

Why This Research Matters

If dynorphin's rapid breakdown can be slowed, its natural pain-relieving properties could be therapeutically enhanced without using synthetic opioids.

The Bigger Picture

Enhancing endogenous opioid peptide activity by protecting them from breakdown represents an alternative approach to pain management that could avoid the side effects and addiction risks of synthetic opioids.

What This Study Doesn't Tell Us

Mouse study with spinal injection — not a practical administration route. The formalin test models inflammatory pain specifically. Peptidase inhibitor side effects not assessed.

Questions This Raises

  • ?Could systemically administered peptidase inhibitors enhance natural pain relief in humans?
  • ?Which specific peptidases are most important for dynorphin degradation in the spinal cord?

Trust & Context

Key Stat:
Extended pain relief duration Peptidase inhibitors significantly prolonged dynorphin-mediated analgesia in the mouse formalin pain test
Evidence Grade:
Moderate animal evidence with clear dose-response data and a well-established pain model.
Study Age:
Published in 1996, contributing to research on enhancing endogenous opioid peptide activity as an alternative to synthetic opioids.
Original Title:
Inhibition of dynorphin-converting enzymes prolongs the antinociceptive effect of intrathecally administered dynorphin in the mouse formalin test.
Published In:
European journal of pharmacology, 314(1-2), 61-7 (1996)
Database ID:
RPEP-00389

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

What are peptidase inhibitors?

Peptidase inhibitors are compounds that block enzymes which break down peptides. By preventing dynorphin's rapid degradation, they allow the body's natural painkiller to work longer before being destroyed.

Why does dynorphin need protection?

Dynorphin is naturally broken down by enzymes within minutes of being released. This rapid degradation limits how long it can provide pain relief, even though the peptide itself is a potent natural analgesic.

Read More on RethinkPeptides

Cite This Study

RPEP-00389·https://rethinkpeptides.com/research/RPEP-00389

APA

Tan-No, K; Taira, A; Sakurada, T; Inoue, M; Sakurada, S; Tadano, T; Sato, T; Sakurada, C; Nylander, I; Silberring, J; Terenius, L; Kisara, K. (1996). Inhibition of dynorphin-converting enzymes prolongs the antinociceptive effect of intrathecally administered dynorphin in the mouse formalin test.. European journal of pharmacology, 314(1-2), 61-7.

MLA

Tan-No, K, et al. "Inhibition of dynorphin-converting enzymes prolongs the antinociceptive effect of intrathecally administered dynorphin in the mouse formalin test.." European journal of pharmacology, 1996.

RethinkPeptides

RethinkPeptides Research Database. "Inhibition of dynorphin-converting enzymes prolongs the anti..." RPEP-00389. Retrieved from https://rethinkpeptides.com/research/tan-no-1996-inhibition-of-dynorphinconverting-enzymes

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.